These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The economics of immunosuppression in renal transplantation: a review of recent literature. Hutton J Transplant Proc; 1999; 31(1-2):1328-32. PubMed ID: 10083592 [No Abstract] [Full Text] [Related]
3. Pharmacoeconomics of Neoral, a new formulation of cyclosporine, in renal transplantation. Abella I Transplant Proc; 1996 Dec; 28(6):3131-4. PubMed ID: 8962213 [No Abstract] [Full Text] [Related]
4. Analysis of cost-effectiveness and cost-utility for immunosuppressive protocols in renal transplantation. Keown P Transplant Proc; 1999; 31(1-2):1140-1. PubMed ID: 10083510 [No Abstract] [Full Text] [Related]
5. Cost analysis of kidney transplantation with cyclosporin A. Cogny-Van Weydevelt F; Dandavino R; Langlois S; Boucher A Transplant Proc; 2000 Mar; 32(2):434-5. PubMed ID: 10715469 [No Abstract] [Full Text] [Related]
6. Pharmaco-economic study of FK 506 (Prograf) and cyclosporine A Neoral in cadaveric renal transplantation. Morris-Stiff G; Richards T; Singh J; Baboolal K; Balaji V; Ostrowski K; Moore R; Darby C; Lord R; Jurewicz WA Transplant Proc; 1998 Jun; 30(4):1285-6. PubMed ID: 9636521 [No Abstract] [Full Text] [Related]
8. Pharmacoeconomic analysis of mycophenolate mofetil versus azathioprine in primary cadaveric renal transplantation. Baker GM; Martin JE; Jang R; Schroeder TJ; Armitstead JA; Myre S; First MR Transplant Proc; 1998 Dec; 30(8):4082-4. PubMed ID: 9865304 [No Abstract] [Full Text] [Related]
9. Economic evaluation of immunosuppressive drugs: an empirical example using a secondary database of hospital charges. Schommer JC; Pathak DS; Grauer DW Transplant Proc; 1996 Apr; 28(2):906. PubMed ID: 8623455 [No Abstract] [Full Text] [Related]
10. Efficacy and safety of low-dose ketoconazole (50 mg) to reduce the cost of cyclosporine in renal allograft recipients. Abraham MA; Thomas PP; John GT; Job V; Shankar V; Jacob CK Transplant Proc; 2003 Feb; 35(1):215-6. PubMed ID: 12591369 [No Abstract] [Full Text] [Related]
11. Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients. Lewis RL; Canafax DM; Pettit KG; DiCesare J; Kaniecki DJ; Arnold RJ; Roberts MS Transplant Proc; 1996 Aug; 28(4):2214-7. PubMed ID: 8769203 [No Abstract] [Full Text] [Related]
12. Pharmacoeconomics of immunosuppressive agents in renal transplant recipients. Bennett WM; Olyaei AJ Transplant Proc; 1999 May; 31(3A Suppl):6S. PubMed ID: 10330949 [No Abstract] [Full Text] [Related]
17. The cost effectiveness of mycophenolate mofetil in the first year after living related renal transplantation. Süleymanlar G; Tuncer M; Sarikaya M; Ersoy F; Aktan S; Yakupoğlu G; Karpuzoğlu T Transplant Proc; 2001 Aug; 33(5):2780-1. PubMed ID: 11498158 [No Abstract] [Full Text] [Related]
18. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Brown RS; Lombardero M; Lake JR Transplantation; 1996 Dec; 62(12):1788-93. PubMed ID: 8990364 [TBL] [Abstract][Full Text] [Related]
19. What happens when an HMO goes AWOL: patients lose immunosuppressives benefit with little warning. Ester D Nephrol News Issues; 1996 Jun; 10(6):31. PubMed ID: 8920433 [No Abstract] [Full Text] [Related]
20. Cost-containment strategies in transplantation: the utility of cyclosporine-ketoconazole combination therapy. Odocha O; Kelly B; Trimble S; Murigande C; Toussaint RM; Callender CO Transplant Proc; 1996 Apr; 28(2):907-9. PubMed ID: 8623456 [No Abstract] [Full Text] [Related] [Next] [New Search]